Sarah Cannon Research Institute

Denver, Colorado 80220

6 studies enrolling now · 36 studies all time

What they study most

Acute Myeloid Leukemia (AML), Advanced Cancer, Advanced Melanoma, Advanced Renal Cell Carcinoma, Advanced Solid Tumor, Advanced Solid Tumor (Phase 1), Advanced Solid Tumors, Advanced or Metastatic Solid Tumors, Biliary Tract Cancer, Bladder Cancer, Brain Cancer, Breast Cancer

Studies at this site

• A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors — Recruiting now
• A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors — Recruiting now
• An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01) — Recruiting now
• Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors — Recruiting now
• A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors — Recruiting now
• A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) — Recruiting now
• AMT-116 in Patients With Advanced Solid Tumors — Recruiting now
• A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors — Running, not enrolling
• Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma — Completed
• A Phase 1/2 Study of Anvumetostat in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors — Completed
• Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors — Running, not enrolling
• Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma — Running, not enrolling
• Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell Liposarcoma — Running, not enrolling
• A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia — Running, not enrolling
• QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations — Running, not enrolling
• A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors — Running, not enrolling
• A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors — Stopped early
• A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma — Stopped early
• Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) — Running, not enrolling
• First in Human Study of TORL-3-600 in Participants With Advanced Cancer — Running, not enrolling
• A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors — Running, not enrolling
• Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma — Completed
• Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL — Stopped early
• A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors — Completed
• A Phase 1 Dose-escalation Study of FF-10832 for Treatment of Solid Tumors Including Biliary Tract Cancer — Running, not enrolling
• A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer — Completed
• First-in-Human Study of IMGC936 in Participants With Advanced Solid Tumors — Completed
• First-in-Human Study of the SHP2 Inhibitor BBP-398 in Patients With Advanced Solid Tumors — Stopped early
• A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of Oral TACH101 in Participants With Advanced or Metastatic Cancer — Status unconfirmed
• Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer — Completed
• Study of MT-5111 in HER2-positive Solid Tumors — Stopped early
• Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors — Completed
• Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE) — Stopped early
• A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6) — Stopped early
• LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE) — Completed
• A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors — Completed